VivoSeq
Infectious Disease

Hepatitis C Virus Infection

67

Pipeline Programs↗

0

Active Trials↗

33

Companies Involved↗

Hepatitis C Virus Infection is a moderately active landscape with 67 programs across 33 companies. The most active players are Alios Biopharma Inc., Peregrine Pharmaceuticals, Boehringer Ingelheim. 22 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

0/100

Mech. Concentration

12/100

Completion Rate

85/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Alios Biopharma Inc.

1 program

Phase 1P

Peregrine Pharmaceuticals

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2S

Salix

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical5

Peginterferon Alfa-2b

Merck & Co.

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Grazoprevir

Merck & Co.

Glecaprevir/pibrentasvir

AbbVie

Antiviral Drugs

Società Italiana Talassemie ed Emoglobinopatie

Phase 15

Bavituximab

Peregrine Pharmaceuticals

Nivolumab

Bristol-Myers Squibb

ACH-0143102

AstraZeneca

AL-611

Alios Biopharma Inc.

GLS-6150

GeneOne Life Science, Inc.

Phase 221

Candesartan

AstraZeneca

Rifaximin

Salix

Infliximab

Organon and Co

Interferon Alfa-2b

Merck & Co.

Interferon

Sanofi

Phase 314

Ezetimibe

Organon and Co

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Interferon Beta-1a

EMD Serono

Simeprevir

Wim Janssens

Approved22

Escitalopram

AbbVie

Ritonavir

AbbVie

Daclatasvir

Bristol-Myers Squibb

Mifepristone

Danco

Boceprevir

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Analysis

Modality Breakdown

96%

Small molecule

73 of 76 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody34%

Small molecule leads; the ring shows all 76 classified programs, each share of the total. Modality classified for 100% of 77 pipeline programs.

Analysis

Trial Status

39

clinical trials

Completed29 · 74%
Unknown status5 · 13%
Terminated4 · 10%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

39 trials

Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.
Completed·HHospital Clinic of Barcelona·Phase 4·NCT00383864·55 enrolled
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
Completed·AbbVie logoAbbVie·Phase 2/3·NCT02486406·64 enrolled
A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection
Completed·Tibotec Pharmaceuticals, Ireland logoTibotec Pharmaceuticals, Ireland·Phase 2·NCT00561353·121 enrolled
Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Completed·Gilead logoGilead·N/A·NCT02591277·3,294 enrolled
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
Completed·Gilead logoGilead·Phase 2·NCT01371578·163 enrolled
An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT02278419·63 enrolled
Treatment of Recently Acquired Hepatitis C Virus Infection
Completed·KKirby Institute·Phase 4·NCT01336010·82 enrolled
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT01700179·8 enrolled
An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection
Completed·TTibotec BVBA·Phase 2·NCT00580801·24 enrolled
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
Completed·TTrek Therapeutics, PBC·Phase 2·NCT02716428·25 enrolled
Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
Completed·Gilead logoGilead·N/A·NCT02562742·554 enrolled
Hepatitis C Virus Infection in Patients With Hemoglobinopathies
Completed·SSocietà Italiana Talassemie ed Emoglobinopatie·N/A·NCT03149289·168 enrolled
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT02250807·40 enrolled
3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT01349465·249 enrolled
Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection
Completed·GGeneOne Life Science, Inc.·Phase 1·NCT03674125·32 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)